Shenzhen Salubris Pharmaceutical Co., Ltd., founded in 1998 and listed in Shenzhen Stock Exchange in 2009 (Stock code: 002294), is comprehensive pharmaceutical groupconsisting of R&D, production and marketing of pharmaceutical products.After years of solid operations, it now ranks Top 10 in the China’spharmaceutical industry in terms of market value and is awarded with the titleof the “20 Most Competitive Listed Pharmaceutical Companies in China” and the“10 Most Valuable Companies Listed on SMEs Board in China”. The Company precisely plans its global industry chain to expand its business to 38countries and regions including China, the United States, Germany, France and Japan.
It takes quality innovative products and evidence-based academic promotion as its core competiveness, ushers in the field of cardiovascular and cerebrovascular and expands in target fields includingantidiabetics, on cology, or thopedics and anti-infection. Through multipleapproaches of proprietary R&D, technological cooperation, investment and M&A, it quickly enriches its product lines, develops many supreme productsand jointly builds an ecological chain for the pharmaceutical industry.
The Group Research Institute consists of three sectors, i.e. R&D forchemicaldrugs, biologics and medical devices, supported by R&D team with nearly a thousand members, including doctors with global educational background, senior experts and senior researchers.
The Company owns a marketing team of more than two thousand medical specialists in China, covering business in thousands of hospitals across Chinese provinces and cities.
The company has many independent intellectual property products, such as Class 1.1 innovativeanti-hypertension drug “Xinlitan” (Allisartan Isoproxil Tablets), the first genericdrug “Taijianing” (Bivalirudin for Injection) of 3.1 type, the most popular antiplatelet aggregation medicine “Taijia” and other high-end prescription medicines.
Salubris adheres to the management philosophy of “Keeping Promises is the Source of Happiness”, making contributions to human health through excellent pharmaceutical products and is determined to become the most influential innovative enterprise for high-end prescription medicine and biomedicine internationalization.
Seven Industrial Bases